04.25.24
FibroBiologics Inc. and Charles River Laboratories, a global provider of drug discovery, development, and manufacturing solutions, have signed a letter of intent allowing for the transfer, testing and validation of FibroBiologics’ technology. This agreement comes ahead of entering into an anticipated master services agreement for the development and manufacture of FibroBiologics’ master cell bank, working cell bank, and fibroblast-based spheroids to be utilized in clinical trials.
FibroBiologics, a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, is investigating the potential treatment of chronic diseases using the immunomodulatory and regenerative capabilities of fibroblasts and fibroblast-derived materials. Indications being studied include degenerative disc disease, multiple sclerosis, wound healing, psoriasis, thymic involution reversal, and cancer.
To help advance FibroBiologics’ fibroblast-based therapies into the clinic, Charles River will conduct feasibility studies on FibroBiologics' cell manufacturing processes within its facility. Additionally, contingent upon entering into a master services agreement, Charles River would serve as the contract development and manufacturing organization (CDMO) responsible for producing drug products for certain FibroBiologics’ clinical trials.
Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics commented, "We are proud to discuss opportunities to work with Charles River, a global leader in cell and gene therapy development and manufacturing, as we look to advance our unique fibroblast-based spheroids into the clinic. We are both committed to bringing innovative and potentially curative therapies to patients suffering from chronic diseases."
FibroBiologics, a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, is investigating the potential treatment of chronic diseases using the immunomodulatory and regenerative capabilities of fibroblasts and fibroblast-derived materials. Indications being studied include degenerative disc disease, multiple sclerosis, wound healing, psoriasis, thymic involution reversal, and cancer.
To help advance FibroBiologics’ fibroblast-based therapies into the clinic, Charles River will conduct feasibility studies on FibroBiologics' cell manufacturing processes within its facility. Additionally, contingent upon entering into a master services agreement, Charles River would serve as the contract development and manufacturing organization (CDMO) responsible for producing drug products for certain FibroBiologics’ clinical trials.
Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics commented, "We are proud to discuss opportunities to work with Charles River, a global leader in cell and gene therapy development and manufacturing, as we look to advance our unique fibroblast-based spheroids into the clinic. We are both committed to bringing innovative and potentially curative therapies to patients suffering from chronic diseases."
